A Study on the Value of Serum Phosphorus Levels in Predicting the Efficacy of Immunotherapy in Patients with Advanced Renal Cancer Serum phosphorus and immunotherapy in renal cancer

Abstract Background Serum biomarkers for predicting immunotherapy outcomes in advanced renal cancer remain an unmet clinical need. This study investigated whether baseline serum phosphorus levels correlate with treatment response and survival in patients receiving immune checkpoint inhibitors (ICIs). Methods We retrospectively analyzed 137 patients with advanced renal cancer treated with ICIs. Receiver operating characteristic (ROC) curves were used to determine the optimal phosphorus cut-off (1.085 mmol/L) for predicting the objective response rate (ORR) to immunotherapy. Whilst the Kaplan-Meier method was employed to plot survival curves and perform Log-rank tests to analyse the relationship between serum phosphorus levels and progression-free survival (PFS) and overall survival (OS). Results ROC curve analysis showed that the area under the curve (AUC) for predicting response to immunotherapy based on baseline serum phosphorus levels was 0.647 (95% CI: 0.550–0.744, P = 0.0057). Kaplan-Meier analysis showed that PFS(P = 0.005) and OS(P = 0.037) were significantly better in the low-serum phosphorus group than in the high-phosphorus group (P = 0.005). Subgroup Kaplan-Meier analysis showed that, in the IMDC intermediate-risk group, serum phosphorus had some predictive power for prognosis (P = 0.013). Multivariate analysis identified elevated serum phosphorus as an independent poor prognostic factor for PFS (HR = 17.537, 95% CI 3.858–79.727, P < 0.001) and OS (HR = 6.286, 95% CI 1.45–27.254, P = 0.014). The clinical benefit rate was higher in the low-phosphorus group (79.4% vs 56.2%). Conclusion High baseline serum phosphorus predicts adverse prognosis in ICI-treated renal cell carcinoma (RCC). It may act as a promising predictive biomarker pending further validation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11501489/v1
Primary Topic
Renal cell carcinoma treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A Study on the Value of Serum Phosphorus Levels in Predicting the Efficacy of Immunotherapy in Patients with Advanced Renal Cancer Serum phosphorus and immunotherapy in renal cancer

Qian Song, Qing Ji, JinChao Chen, Sheng Wang et al.
2 links
Research Square
Renal cell carcinoma treatment
preprint

A Study on the Value of Serum Phosphorus Levels in Predicting the Efficacy of Immunotherapy in Patients with Advanced Renal Cancer Serum phosphorus and immunotherapy in renal cancer

Qian Song, Qing Ji, JinChao Chen, Sheng Wang, Yue Zhou, Zihan Lin
preprint en

Abstract

Abstract Background Serum biomarkers for predicting immunotherapy outcomes in advanced renal cancer remain an unmet clinical need. This study investigated whether baseline serum phosphorus levels correlate with treatment response and survival in patients receiving immune checkpoint inhibitors (ICIs). Methods We retrospectively analyzed 137 patients with advanced renal cancer treated with ICIs. Receiver operating characteristic (ROC) curves were used to determine the optimal phosphorus cut-off (1.085 mmol/L) for predicting the objective response rate (ORR) to immunotherapy. Whilst the Kaplan-Meier method was employed to plot survival curves and perform Log-rank tests to analyse the relationship between serum phosphorus levels and progression-free survival (PFS) and overall survival (OS). Results ROC curve analysis showed that the area under the curve (AUC) for predicting response to immunotherapy based on baseline serum phosphorus levels was 0.647 (95% CI: 0.550–0.744, P = 0.0057). Kaplan-Meier analysis showed that PFS(P = 0.005) and OS(P = 0.037) were significantly better in the low-serum phosphorus group than in the high-phosphorus group (P = 0.005). Subgroup Kaplan-Meier analysis showed that, in the IMDC intermediate-risk group, serum phosphorus had some predictive power for prognosis (P = 0.013). Multivariate analysis identified elevated serum phosphorus as an independent poor prognostic factor for PFS (HR = 17.537, 95% CI 3.858–79.727, P < 0.001) and OS (HR = 6.286, 95% CI 1.45–27.254, P = 0.014). The clinical benefit rate was higher in the low-phosphorus group (79.4% vs 56.2%). Conclusion High baseline serum phosphorus predicts adverse prognosis in ICI-treated renal cell carcinoma (RCC). It may act as a promising predictive biomarker pending further validation.

Research Square
Zhejiang Chinese Medical University (CN), Chinese Academy of Sciences (CN), Zhejiang Cancer Hospital (CN)
National Natural Science Foundation of China
Good health and well-being
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon